Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 799 across all filing types
Latest filing 2020-03-05 Earnings Release
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming Group Reports Strong Preliminary (Unaudited) Financial Results for 2019
Earnings Release Classification · 100% confidence The document presents 'preliminary (unaudited) financial results for 2019' including detailed income statement and balance sheet summaries, revenue figures, net profits, and CEO commentary on performance and strategy. This content structure is characteristic of a comprehensive annual financial report, although it is labeled 'preliminary'. Given the extensive nature of the financial data and commentary covering the full fiscal year, it aligns most closely with the content of an Annual Report (10-K), even if it precedes the final audited version. It is not merely an Earnings Release (ER) which is typically shorter and focuses only on highlights, nor is it a quarterly report (IR) as it covers the full year. Since the document provides the full financial narrative and data, it is classified as the Annual Report (10-K) content type. FY 2019
2020-03-05 English
Pharming receives EMA approval of new facility for expansion of RUCONEST® production
Regulatory Filings Classification · 95% confidence The document is a press release dated January 21, 2020, announcing that Pharming Group N.V. received EMA approval for a new production facility for its product RUCONEST®. It details operational updates, capacity increases, and future expectations (FDA review, H1 2020). This type of announcement, focusing on operational milestones, regulatory approvals, and business updates outside of mandated periodic financial reports (like 10-K or IR), typically falls under general regulatory announcements or news releases. Since it is not a formal financial report (10-K, IR, ER, MRQ), nor a specific corporate action like a dividend (DIV) or share transaction (POS), the most appropriate classification is Regulatory Filings (RNS), which serves as a broad category for significant, non-standard corporate news releases that are filed with regulators. It is not an Earnings Release (ER) as it focuses on production capacity, not financial results. It is not an Investor Presentation (IP) or Fund Factsheet (FS). It is a news announcement, making RNS the best fit among the provided options for a general, material corporate update.
2020-01-21 English
Pharming announces the placement of €125 million senior unsecured convertible bonds due 2025
Capital/Financing Update Classification · 99% confidence The document is a press release announcing the placement of €125 million in senior unsecured convertible bonds. This action directly relates to the company's fundraising, financing activities, and capital structure changes (refinancing a loan, issuing new debt instruments). This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific corporate finance event.
2020-01-15 English
Pharming announces the launch of an offering of approximately €125 million senior unsecured convertible bonds due 2025
Capital/Financing Update Classification · 98% confidence The document is a press release announcing the launch of an offering of senior unsecured convertible bonds (€125 million). This activity involves fundraising, debt maturity extension, and capital structure changes. This directly aligns with the definition of 'Capital/Financing Update' (Code: CAP). Although it is a press release, its primary content is the financing event itself, not merely announcing the publication of a separate report (which would be RPA or RNS). The document details the terms of the bonds, their purpose (redeeming a loan, funding expansion), and the expected closing date.
2020-01-14 English
Pharming reacquires RUCONEST®-licensed territories from Sobi
M&A Activity Classification · 99% confidence The document is a press release dated December 30, 2019, announcing a definitive agreement between Pharming and Sobi to reacquire commercial rights for the product RUCONEST® in 36 territories. It details the financial terms (€7.5 million payment) and the immediate impact on earnings. This type of announcement, detailing a significant corporate transaction (reacquisition of commercial rights/asset restructuring) that is not a standard periodic financial report (10-K, IR, ER), fits best under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if no other category applies. Since it involves a significant financial transaction and change in capital structure related to asset ownership, CAP is a strong candidate. However, given the nature of the announcement—a specific corporate action/transaction—and the lack of a specific category for M&A or asset acquisition (TAR is for M&A proposals/takeover bids), this is a material corporate event announcement. It is not a standard earnings release (ER), interim report (IR), or a proxy statement. Given the options, 'Capital/Financing Update (CAP)' covers significant financial restructuring/asset acquisition payments. Alternatively, if it were purely an announcement of a transaction without financial details, RNS might apply. Since it details a €7.5M payment and immediate accretion to earnings, CAP is the most appropriate fit among the specific choices for a material corporate transaction announcement.
2019-12-30 English
Pharming Group reports strong interim financial results for the first nine months of 2019
Earnings Release Classification · 100% confidence The document text begins with a clear headline: "Pharming Group reports strong interim financial results for the first nine months of 2019". It then provides a financial summary for the "9 months to 30 September" and explicitly states: "Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) presents its (unaudited) interim financial report for the first nine months and the third quarter ended 30 September 2019." This content is a comprehensive financial report covering a period shorter than a full year (nine months), which directly matches the definition of an Interim / Quarterly Report (Code: IR). It is not a brief announcement (RPA) as the document text provided is extensive (591,329 characters, though truncated for display, the context implies a full report structure). 9M 2019
2019-10-24 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.